MAB21L4 Deficiency Drives Squamous Cell Carcinoma via Activation of RET.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
02 09 2022
Historique:
received: 07 01 2022
revised: 02 05 2022
accepted: 10 06 2022
pubmed: 16 6 2022
medline: 9 9 2022
entrez: 15 6 2022
Statut: ppublish

Résumé

Epithelial squamous cell carcinomas (SCC) most commonly originate in the skin, where they display disruptions in the normally tightly regulated homeostatic balance between keratinocyte proliferation and terminal differentiation. We performed a transcriptome-wide screen for genes of unknown function that possess inverse expression patterns in differentiating keratinocytes compared with cutaneous SCC (cSCC), leading to the identification of MAB21L4 (C2ORF54) as an enforcer of terminal differentiation that suppresses carcinogenesis. Loss of MAB21L4 in human cSCC organoids increased expression of RET to enable malignant progression. In addition to transcriptional upregulation of RET, deletion of MAB21L4 preempted recruitment of the CacyBP-Siah1 E3 ligase complex to RET and reduced its ubiquitylation. In SCC organoids and in vivo tumor models, genetic disruption of RET or selective inhibition of RET with BLU-667 (pralsetinib) suppressed SCC growth while inducing concomitant differentiation. Overall, loss of MAB21L4 early during SCC development blocks differentiation by increasing RET expression. These results suggest that targeting RET activation is a potential therapeutic strategy for treating SCC. Downregulation of RET mediated by MAB21L4-CacyBP interaction is required to induce epidermal differentiation and suppress carcinogenesis, suggesting RET inhibition as a potential therapeutic approach in squamous cell carcinoma.

Identifiants

pubmed: 35705526
pii: 704905
doi: 10.1158/0008-5472.CAN-22-0047
pmc: PMC9444977
mid: NIHMS1818583
doi:

Substances chimiques

CACYBP protein, human 0
Calcium-Binding Proteins 0
Proto-Oncogene Proteins c-ret EC 2.7.10.1
RET protein, human EC 2.7.10.1
MAB21L4 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3143-3157

Subventions

Organisme : Doris Duke Charitable Foundation
ID : 2018094
Pays : United States
Organisme : Doris Duke Charitable Foundation
ID : 2018094A
Pays : United States
Organisme : NIAMS NIH HHS
ID : K01 AR070895
Pays : United States

Informations de copyright

©2022 American Association for Cancer Research.

Références

Database (Oxford). 2017 Jan 1;2017:
pubmed: 28605766
Oncogene. 2021 Nov;40(44):6299-6307
pubmed: 34584216
Nat Med. 2010 Dec;16(12):1450-5
pubmed: 21102459
Sci Signal. 2017 Sep 12;10(496):
pubmed: 28900043
Cancer Discov. 2018 Jul;8(7):836-849
pubmed: 29657135
J Invest Dermatol. 2014 Oct;134(10):2630-2638
pubmed: 24662767
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503
pubmed: 31691815
Genes Dis. 2019 Oct 19;8(2):181-192
pubmed: 33997165
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Cancer Cell. 2009 Jun 2;15(6):477-88
pubmed: 19477427
Nucleic Acids Res. 2019 Jul 2;47(W1):W171-W174
pubmed: 31106371
Nat Commun. 2016 Aug 30;7:12601
pubmed: 27574101
Nature. 2013 Jan 10;493(7431):231-5
pubmed: 23201690
Oncogene. 2009 May 14;28(19):2034-45
pubmed: 19363524
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Nat Commun. 2014;5:3116
pubmed: 24445538
J Invest Dermatol. 2018 Dec;138(12):2684-2687
pubmed: 29932941
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Nat Rev Cancer. 2018 Nov;18(11):696-705
pubmed: 30293088
Genes Dev. 2006 Nov 15;20(22):3185-97
pubmed: 17114587
J Cell Sci. 2017 Oct 1;130(19):3282-3296
pubmed: 28794017
Sci Transl Med. 2018 Aug 22;10(455):
pubmed: 30135250
Exp Dermatol. 2021 Nov;30(11):1711-1716
pubmed: 34036652
Front Genet. 2019 Sep 03;10:775
pubmed: 31552090
Cell Cycle. 2009 Sep 1;8(17):2819-27
pubmed: 19667759
Cancer Res. 2008 May 15;68(10):3743-51
pubmed: 18483257
EBioMedicine. 2020 Jul;57:102835
pubmed: 32574963
J Biol Chem. 2005 Apr 8;280(14):13442-9
pubmed: 15677445
Mol Biol Cell. 2000 Feb;11(2):453-66
pubmed: 10679006
J Clin Oncol. 2020 Sep 1;38(25):2916-2925
pubmed: 32673170
Mol Cell. 2001 May;7(5):915-26
pubmed: 11389839
Nat Commun. 2018 Nov 16;9(1):4821
pubmed: 30446652
Carcinogenesis. 2018 Mar 8;39(3):418-428
pubmed: 29186361
Nat Commun. 2018 Sep 10;9(1):3667
pubmed: 30202019
Nucleic Acids Res. 2019 Jul 2;47(W1):W212-W224
pubmed: 31114921
Clin Cancer Res. 2017 Apr 15;23(8):1988-1997
pubmed: 27683183
Curr Protoc Protein Sci. 2018 Feb 21;91:19.23.1-19.23.15
pubmed: 29516480
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873
pubmed: 27100738
Nat Methods. 2013 Aug;10(8):730-6
pubmed: 23921808
Oncogene. 2011 Nov 17;30(46):4666-77
pubmed: 21602893
Cell Rep. 2018 Oct 30;25(5):1332-1345.e5
pubmed: 30380422
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Clin Cancer Res. 2021 Oct 15;27(20):5452-5456
pubmed: 34045295
Nat Methods. 2018 Mar;15(3):207-212
pubmed: 29400715
JAMA Dermatol. 2016 Apr;152(4):419-28
pubmed: 26762219
Oncogene. 2002 Feb 28;21(10):1527-38
pubmed: 11896581
Cell. 2019 Jan 10;176(1-2):361-376.e17
pubmed: 30580963
Amino Acids. 2011 Oct;41(4):773-80
pubmed: 20182755
Front Pharmacol. 2020 Jul 21;11:1112
pubmed: 32848739
J Invest Dermatol. 2018 Jun;138(6):1445-1449
pubmed: 29360484
Sci Rep. 2020 Feb 27;10(1):3637
pubmed: 32108138
Oncogene. 1998 Oct 8;17(14):1885-8
pubmed: 9778055
PeerJ. 2017 Aug 21;5:e3631
pubmed: 28852586
J Cell Biol. 2007 Dec 31;179(7):1599-612
pubmed: 18166659
Cell. 2017 Jul 27;170(3):564-576.e16
pubmed: 28753430
J Invest Dermatol. 2018 Dec;138(12):2558-2567
pubmed: 29964033
EMBO J. 2017 Oct 16;36(20):3029-3045
pubmed: 28899900
Genome Biol. 2008 Oct 30;9(10):R157
pubmed: 18973690
J Clin Endocrinol Metab. 2010 Nov;95(11):E342-6
pubmed: 20702524
J Biol Chem. 2005 Oct 7;280(40):34278-87
pubmed: 16085652
Drugs. 2020 Nov;80(17):1865-1870
pubmed: 33136236
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
N Engl J Med. 2018 Jul 26;379(4):341-351
pubmed: 29863979
Nat Methods. 2011 Jan;8(1):70-3
pubmed: 21131968
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W305-11
pubmed: 19465376
Dev Biol. 2012 May 1;365(1):101-9
pubmed: 22360967
Nature. 1994 Jan 27;367(6461):380-3
pubmed: 8114940

Auteurs

Ankit Srivastava (A)

Stanford Program in Epithelial Biology, Stanford University, Stanford, California.
Department of Microbiology, Tumor and Cell Biology, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden.

Cristina Tommasi (C)

Stanford Program in Epithelial Biology, Stanford University, Stanford, California.

Dane Sessions (D)

Stanford Program in Epithelial Biology, Stanford University, Stanford, California.

Angela Mah (A)

Stanford Program in Epithelial Biology, Stanford University, Stanford, California.

Tomas Bencomo (T)

Stanford Program in Epithelial Biology, Stanford University, Stanford, California.

Jasmine M Garcia (JM)

Stanford Program in Epithelial Biology, Stanford University, Stanford, California.

Tiffany Jiang (T)

Stanford Program in Epithelial Biology, Stanford University, Stanford, California.

Michael Lee (M)

Stanford Program in Epithelial Biology, Stanford University, Stanford, California.

Joseph Y Shen (JY)

Stanford Program in Epithelial Biology, Stanford University, Stanford, California.

Lek Wei Seow (LW)

Stanford Program in Epithelial Biology, Stanford University, Stanford, California.

Audrey Nguyen (A)

Stanford Program in Epithelial Biology, Stanford University, Stanford, California.

Kimal Rajapakshe (K)

Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.

Cristian Coarfa (C)

Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.

Kenneth Y Tsai (KY)

Departments of Anatomic Pathology & Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute; Tampa, Florida.

Vanessa Lopez-Pajares (V)

Stanford Program in Epithelial Biology, Stanford University, Stanford, California.

Carolyn S Lee (CS)

Stanford Program in Epithelial Biology, Stanford University, Stanford, California.
Veterans Affairs Palo Alto Healthcare System, Palo Alto, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH